-TradeXChange
Turning Point Shares Plunge After Highlighting Updated Data From Lead Program In Pretreated Lung Cancer Patients
Turning Point Therapeutics Inc (NASDAQ:TPTX) has announced additional preliminary data from ongoing trials of lead drug candidate repotrectinib and elzovantinib (TPX-0022). …